Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Sanofi Pasteur, a Sanofi Company

Conditions

Diphtheria ImmunisationHaemophilus Influenzae Type b ImmunisationHepatitis B ImmunisationMeasles ImmunisationMumps ImmunisationPertussis ImmunisationPneumococcal ImmunisationPneumococcal Infection

Phase 2

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

CompletedNCT01654263

National Institute of Allergy and Infectious Diseases (NIAID)Pneumococcal Infection

Start: 2012-10-10End: 2015-08-21Updated: 2017-03-27

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

CompletedNCT04398706

Sanofi Pasteur, a Sanofi CompanyDiphtheria Immunisation, Haemophilus Influenzae Type b Immunisation, Hepatitis B Immunisation +8

Start: 2020-05-22End: 2023-08-10Updated: 2025-09-08